Abstract
Scirrhous gastric carcinoma is a special type of gastric carcinomas and accompanied with highly interstitial fibrosis and diffuse cellular infiltration. Scirrhous gastric carcinoma is mainly composed of poor-differentiated adenocarcinoma and signet-ring cell carcinoma, with the clinical features of Borramann 4, thickening and stenosis of stomach wall, high peritoneal and lymph node metastases rates and poor prognosis. R0 resection and postoperative chemotherapy with S-1 as a main way are necessary for the patients who are able to undergo curable resection. The palliative operation should be applied to patients with ileus and urinary obstructions caused by peritoneal metastasis because of limited effect of surgical treatment. Chemo-therapy is the best choice for patients who are not able to undergo curable resection, conversional therapy can improve the prognosis of patients, and preoperative S-1/CDDP combination chemotherapy is an expectable therapy. Moreover, controlling peritoneal metastasis and effect of intraperitoneal chemotherapy are much anticipated. The efficiency of molecular targeted therapy by bevacizumab and gene therapy by adenovirus remain further study. Key words: Gastric neoplasms, scirrhous; Surgical procedures, operative; Chemotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
